Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)

Tarsus Pharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics beginning with eye care. The company launched XDEMVY lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis in August 2023 after receiving U. S. Food and Drug Administration approval in July 2023. XDEMVY targets the Demodex mite infestation that underlies the disease. In addition to its marketed product, Tarsus is advancing a pipeline that includes TP-04 an investigational sterile gel formulation of lotilaner for potential ocular rosacea treatment and TP-05 an oral tablet formulation of lotilaner for potential Lyme disease prophylaxis. The company’s research and development activities are centered on leveraging the antiparasitic properties of lotilaner to address unmet medical needs.

Tarsus Pharmaceuticals generates revenue principally from product sales of XDEMVY to eye care professionals and patients through prescriptions. The company also receives license fees, milestone payments and royalties from collaboration agreements such as the arrangement with GrandPharma for the Greater China territory. In 2025 XDEMVY accounted for the majority of the company’s net product sales which exceeded $450 million for the full year. Revenue is recognized upon transfer of control of the product to customers and the company relies on contract manufacturers for production.

Tarsus Pharmaceuticals occupies a distinctive position in the eye care therapeutics market as the first and only company with an FDA approved treatment for Demodex blepharitis. XDEMVY is regarded by the company as the standard of care for this condition which previously had no approved therapies and relied on off label remedies such as tea tree oil or lid wipes. Competitors in the space are largely early stage including Azura Ophthalmics, Atticus Medical, and Glaukos Corporation which are conducting preclinical or clinical studies for Demodex targeted products. Tarsus’s competitive advantages stem from its novel mechanism of action that selectively inhibits parasite specific GABA chloride channels without affecting human receptors, its robust intellectual property portfolio covering the lotilaner compound, and its early commercial traction that has generated strong brand awareness among ophthalmologists and optometrists.

Tarsus Pharmaceuticals sells XDEMVY primarily to eye care specialists including ophthalmologists and optometrists who prescribe the medication to patients suffering from Demodex blepharitis. The product is also accessed by patients through retail and specialty pharmacies under prescription coverage. While the filing does not disclose specific customer names the company’s commercial strategy targets the approximately nine million individuals in the United States who are actively seeking treatment for Demodex blepharitis or related ocular conditions, as well as broader disease awareness initiatives aimed at increasing diagnosis rates among the estimated twenty five million affected individuals.